v3.25.4
Reverse Recapitalization and Sonnet Acquisition (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
Jul. 11, 2025
Dec. 31, 2025
Dec. 02, 2025
Jun. 30, 2025
Business Combination [Line Items]        
Common stock, par or stated value per share   $ 0.01   $ 0.01
Common Stock [Member]        
Business Combination [Line Items]        
Common stock, par or stated value per share     $ 0.01  
Rorschach Advisors LLC [Member]        
Business Combination [Line Items]        
Number of cryptocurrency token 12.5      
Cryptocurrency token value $ 411,300      
Loss on commitment on cryptocurrency token $ 169,200      
Rorschach Advisors LLC [Member] | Common Stock [Member]        
Business Combination [Line Items]        
Common stock, par or stated value per share $ 1.25      
Stock issued during period, shares, new issues 7,761,860      
Rorschach and Sonnet Merger [Member]        
Business Combination [Line Items]        
Number of cryptocurrency token 12.5      
Rorschach and Sonnet Merger [Member] | Common Stock [Member]        
Business Combination [Line Items]        
Stock issued during period, value, new issues $ 299,900      
Sonnet BioTherapeutics Holdings, Inc. [Member]        
Business Combination [Line Items]        
Stock issued during period, shares, new issues 3,680,346      
Stock issued during period, value, new issues $ 17,800      
Total net assets acquired 44,834      
Total cost of the acquisition 44,834      
Transaction costs 9,324      
Sonnet BioTherapeutics Holdings, Inc. [Member] | Common Stock [Member]        
Business Combination [Line Items]        
Stock issued during period, value, new issues $ 17,771      
Sonnet BioTherapeutics Holdings, Inc. [Member] | Warrant [Member]        
Business Combination [Line Items]        
Stock issued during period, shares, new issues 2,400,000      
Stock issued during period, value, new issues $ 12,478      
Cash payment to settle outstanding warrants $ 5,261